Company intelligence / Profile preview

Hexima

Melbourne, Victoria, Australiahexima.com.au ↗

Ownership: Public · HXL
Development stage: Other

Overview

Hexima Limited develops plant-derived proteins and peptides as human antifungal therapeutics. The company has advanced to clinical-stage development, but specific clinical trial results are not detailed in the available sources.

Therapeutic areas: Infectious Diseases
Modalities: ProteinPeptidesBiologic
Industry: Biotech

Drug pipeline

1 asset

pezadeftide

Discontinued

Financials

Market cap: $6.9B
Total revenue: $529.3M
Enterprise value: $7.8B

Beyond the preview

Go deeper on Hexima.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hexima.

Explore the full profile